These claims broadly cover URG101 and its use in the treatment of painful bladder syndrome (PBS) by administering a glycosaminoglycan (such as heparin) and a local anesthetic.
Urigen recently closed a Phase II study of URG101 due to positive, statistically significant results at interim analysis with 50% patient enrollment. Based on these results, Urigen plans to advance the project into late-stage clinical development.
William Garner, Urigen’s president and CEO, said: “URG101 offers the potential to bring standardization to the treatment of PBS with the first FDA-approved product in a market conservatively estimated at $300-400 million annually in the US.”